Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
1970743 | Clinical Biochemistry | 2006 | 5 Pages |
Objectives:Rasburicase (Fasturtec®) is used to prevent or treat hyperuricemia associated with chemotherapy. We developed a capillary zone electrophoresis method to measure urinary allantoin, the degradation product of uric acid by rasburicase.Design and methods:Electrophoresis was performed using a P/ACE 5500 system (Beckman) with a fused silica capillary tube and a UV–visible detector set at 214 nm. Urine samples from 10 patients with non-Hodgkin’s lymphoma were analyzed to validate the technique.Results:Using a sodium tetraborate running buffer, urinary allantoin was separated from related compounds and internal standard in less than 30 min. The method was linear up to 1.25 g/L (quantification limit: 30 mg/L); precision was below 10%. The total amount of allantoin excreted in patients treated by rasburicase ranged from 1.5 g to 7.9 g/4 days.Conclusion:This CZE assay is a simple, rapid and reproducible method to measure allantoin in urine. Different elimination profiles have been found in patients treated with rasburicase.